New DurAVR TAVR System Shows Promise in Treating Severe Aortic Stenosis

Anteris Technologies’ groundbreaking DurAVR TAVR system, designed to replicate a healthy aortic valve, shows early promise in treating severe aortic stenosis. Initial one-year data presented at SCAI 2024 reveal successful procedures with excellent hemodynamic results and no valve-related complications. Dr. Azeem Latib expresses excitement over the system’s potential to enhance blood flow characteristics. While awaiting FDA approval, the cardiology community eagerly anticipates further data releases on this innovative TAVR system.